ORGANIZATION

• Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
  February 9, 2026

• Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
  February 6, 2026

• FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
  February 3, 2026

• AMDD to Continue Policy Advocacy to Address Device Lag and Loss: Chair
  January 28, 2026

• Off-Year Drug Price Revisions Run Counter to Innovation, JPMA Exec Says
  January 23, 2026

• Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
  January 21, 2026

• OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
  January 20, 2026

• JETRO Picks 10 Overseas Startups for Regenerative Medicine Japan Entry Program
  January 20, 2026

• Pharma FTC Clarifies “Simple Beverages” under New Food Rules
  January 14, 2026

• EFPIA Japan Appoints Novartis’ Pullicino as Vice Chair
  January 9, 2026

• FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
  January 6, 2026

• Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
  January 6, 2026

• Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
  January 5, 2026

• Generic Use Rate Rises Further to 89.5% in July-September: JGA
  January 5, 2026

• Trade Groups Hail Spillover Abolition, but Urge Further Overhauls
  December 26, 2025

• EFPIA Japan, Patient Groups Call for Stronger Health Literacy, PPI
  December 22, 2025

• JPMA Exec Renews Call for Simpler Drug Pricing System
  December 19, 2025

• JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
  December 18, 2025

• Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
  December 17, 2025

• Japan Medical Societies Recommend RSV Vaccination for Older Adults
  December 15, 2025

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »